Home » Vetter Pharma-Fertigung Launches Major Expansion
Vetter Pharma-Fertigung Launches Major Expansion
PharmaManufacturing.com
06/22/2005
Scheduled for completion by the fall of 2006, Vetter's new state-of-the-art facility will increase its production capacity by more than 30 percent and allow Vetter to broaden its product portfolio. The company is presently capable of producing more than 300 million pre-filled syringe systems per year at its various sites.
Vetter's new facility is being built in the vicinity of the existing production lines. Each location operates independently and can be used at all times as a fully operational back-up facility. By duplicating the production lines, Vetter is providing its customers with considerable delivery and process security. For over 15 years, Vetter’s production facilities have been inspected regularly by international regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency (EMEA), as well as its customers.
Vetter Pharma-Fertigung GmbH & Co. KG has been active as an independent pharmaceutical service partner for more than 50 years. Twenty-five years ago, Vetter began focusing on the aseptic production of liquid and lyophilized drugs. In addition to standard injection systems and cartridges, the company also offers its own administration systems, such as the Vetter Lyo-Ject dual-chamber syringe. Vetter currently has more than 127 patents to its name, including solutions to prevent counterfeiting and piracy. The company offers a variety of services through its three branches: Development Service, for product development from manufacturing to launch; Commerical Manufacturing, for start-to-finish manufacturing operations; and Solutions, which specializes in application systems.
For more information, contact:
Vetter Pharma-Fertigung GmbH & Co. KG
Schützenstraße 87
88212 Ravensburg
Telephone: +49 751 3700 0
Fax: (0751) 37 00-40 00
E-Mail: info@vetter-pharma.com
www.vetter-pharma.com
More News:
- 02/08/2010 EMA Releases Road Map Through 2015
- 02/08/2010 One-Third of Antimalarial Medicines Sampled in Three African Nations Found to be Substandard in Large-Scale USP-WHO Study
- 02/05/2010 FDA Aims to Identify Risky Food, Drug ImportsFrom MSNBC.com
- 02/04/2010 Bristol-Myers Squibb to Freeze Salaries in 2010From WSJ.com
- 02/03/2010 Lilly Transfers Funds, Technology to Aspen in TB Partnership
- 02/03/2010 Teva, Amgen Duke It Out Over Generic BiotechFrom WSJ.com
- 02/02/2010 A Cause for Optimism: Global Manufacturing Surges
- 01/28/2010 Novartis’s Jimenez Beats Out Reinhardt to Replace CEO VasellaFrom BusinessWeek.com
- 01/28/2010 Register For Stevens Institute of Technology’s Spring II 2010 Semester
- 01/28/2010 AstraZeneca to Cut 8,000 Jobs Amid Weak EarningsFrom ABCNews.com
- All news »
More content on this topic:
Get Connected Now!
- Featured White Papers

Print page